Fiona Collinson

4.7k total citations · 1 hit paper
41 papers, 1.2k citations indexed

About

Fiona Collinson is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Fiona Collinson has authored 41 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 6 papers in Genetics. Recurrent topics in Fiona Collinson's work include Renal cell carcinoma treatment (9 papers), Cancer Immunotherapy and Biomarkers (6 papers) and CAR-T cell therapy research (5 papers). Fiona Collinson is often cited by papers focused on Renal cell carcinoma treatment (9 papers), Cancer Immunotherapy and Biomarkers (6 papers) and CAR-T cell therapy research (5 papers). Fiona Collinson collaborates with scholars based in United Kingdom, United States and Australia. Fiona Collinson's co-authors include David Jayne, Julia Brown, Helen Marshall, Philip Quirke, P J Guillou, Sue Pavitt, Jenifer Barrie, Judy Wright, Carolyn J. Murray and Helen Howard and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Fiona Collinson

37 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-term follow-up of the Medical Research Council CLASICC trial of conventionalversuslaparoscopically assisted resection in colorectal cancer

2012 471 citations Helen Marshall, Fiona Collinson et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fiona Collinson United Kingdom	14	872	633	313	105	95	41	1.2k
Marcos V. Perini Australia	18	477 0.5×	567 0.9×	336 1.1×	31 0.3×	106 1.1×	97	1.2k
Felice N. van Erning Netherlands	23	997 1.1×	597 0.9×	416 1.3×	113 1.1×	76 0.8×	90	1.5k
Mesut Şeker Türkiye	17	615 0.7×	410 0.6×	488 1.6×	79 0.8×	109 1.1×	98	1.3k
Alessandro Paniccia United States	21	1.1k 1.2×	631 1.0×	509 1.6×	36 0.3×	85 0.9×	106	1.4k
Peter Klare Germany	19	754 0.9×	340 0.5×	372 1.2×	313 3.0×	147 1.5×	89	1.3k
Rainer Kube Germany	19	1.1k 1.2×	755 1.2×	419 1.3×	97 0.9×	89 0.9×	45	1.5k
Paolo Goffredo United States	21	444 0.5×	911 1.4×	198 0.6×	121 1.2×	99 1.0×	85	1.6k
Ilaria Bossi Italy	18	569 0.7×	386 0.6×	275 0.9×	91 0.9×	185 1.9×	37	1.1k
Gagandeep Singh United States	18	799 0.9×	641 1.0×	325 1.0×	16 0.2×	147 1.5×	98	1.5k
Neal Wilkinson United States	18	410 0.5×	677 1.1×	490 1.6×	64 0.6×	73 0.8×	40	1.0k

Countries citing papers authored by Fiona Collinson

Since Specialization

Citations

This map shows the geographic impact of Fiona Collinson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fiona Collinson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fiona Collinson more than expected).

Fields of papers citing papers by Fiona Collinson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fiona Collinson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fiona Collinson. The network helps show where Fiona Collinson may publish in the future.

Co-authorship network of co-authors of Fiona Collinson

This figure shows the co-authorship network connecting the top 25 collaborators of Fiona Collinson. A scholar is included among the top collaborators of Fiona Collinson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fiona Collinson. Fiona Collinson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hussain, Syed A., Angela Green, Irbaz Bin Riaz, et al.. (2025). A phase Ib window of opportunity study of atezolizumab administered intravesically or direct injection in patients undergoing radical cystectomy for bladder cancer: Results of the single dose cohorts.. Journal of Clinical Oncology. 43(5_suppl). 773–773.

Savage, Joshua, Amit Patel, Fiona Collinson, et al.. (2024). A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial. BMC Cancer. 24(1). 83–83. 14 indexed citations

Hussain, Syed A., et al.. (2024). INVEST: A phase Ib window of opportunity study of atezolizumab administered either intravesically or direct tumour injection in patients with bladder cancer prior to radical cystectomy.. Journal of Clinical Oncology. 42(4_suppl). TPS710–TPS710. 1 indexed citations

Hull, Mark A., Sharon Ruddock, Tim Brend, et al.. (2023). Randomised, placebo-controlled, phase 3 trial of the effect of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) on colorectal cancer recurrence and survival after surgery for resectable liver metastases: EPA for Metastasis Trial 2 (EMT2) study protocol. BMJ Open. 13(11). e077427–e077427. 2 indexed citations

Vasudev, Naveen, Sarah Brown, Tom Waddell, et al.. (2021). LBA29 Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM). Annals of Oncology. 32. S1304–S1305. 4 indexed citations

Brown, Janet E., Catherine Handforth, Juliet Compston, et al.. (2020). Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. Journal of bone oncology. 25. 100311–100311. 41 indexed citations

Kamposioras, Konstantinos, et al.. (2020). P-126 Markers of tumour inflammation are prognostic for overall survival in patients with advanced pancreatic ductal adenocarcinoma receiving FOLFIRINOX chemotherapy. Annals of Oncology. 31. S131–S131. 1 indexed citations

Buckley, Hannah, Fiona Collinson, Louise Flanagan, et al.. (2019). PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma. BMC Cancer. 19(1). 1102–1102. 13 indexed citations

Franks, K., M. Snee, Babu Naidu, et al.. (2017). P1.05-029 SABRTOOTH-A Feasibility Study of SABR Compared to Surgery in Patients with Peripheral Stage I NSCLC Considered to Be at Higher Risk from Surgery. Journal of Thoracic Oncology. 12(1). S631–S632. 1 indexed citations

10.

Snee, M., Lucy McParland, Fiona Collinson, et al.. (2016). The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I non-small cell lung cancer (NSCLC) considered to be at higher risk of complications from surgical resection. Pilot and Feasibility Studies. 2(1). 5–5. 28 indexed citations

11.

Collinson, Fiona, Wendi Qian, Roldano Fossati, et al.. (2014). Optimal treatment of early-stage ovarian cancer. Annals of Oncology. 25(6). 1165–1171. 62 indexed citations

12.

Collinson, Fiona, Rachel A. Craven, David A. Cairns, et al.. (2013). Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection. Clinical Cancer Research. 19(18). 5227–5239. 58 indexed citations

13.

Barrie, Jenifer, David Jayne, Judy Wright, et al.. (2013). Attaining Surgical Competency and Its Implications in Surgical Clinical Trial Design: A Systematic Review of the Learning Curve in Laparoscopic and Robot-Assisted Laparoscopic Colorectal Cancer Surgery. Annals of Surgical Oncology. 21(3). 829–840. 103 indexed citations

14.

Collinson, Fiona, Jenny F. Seligmann, & Timothy Perren. (2012). Ovarian Cancer: Advances in First-Line Treatment Strategies with a Particular Focus on Anti-Angiogenic Agents. Current Oncology Reports. 14(6). 509–518. 9 indexed citations

15.

Collinson, Fiona, David Jayne, Alessio Pigazzi, et al.. (2011). An international, multicentre, prospective, randomised, controlled, unblinded, parallel-group trial of robotic-assisted versus standard laparoscopic surgery for the curative treatment of rectal cancer. International Journal of Colorectal Disease. 27(2). 233–241. 182 indexed citations

16.

Collinson, Fiona, Janet E. Brown, Christopher McCabe, et al.. (2011). The STAR trial: can quality of life benefit offset any survival detriment?. Trials. 12(S1). 1 indexed citations

17.

Collinson, Fiona, et al.. (2010). Sunitinib-induced severe hypothyroidism with cardiac compromise. Medical Oncology. 28(S1). 699–701. 6 indexed citations

18.

Collinson, Fiona & Gordon C. Jayson. (2009). New therapeutic agents in ovarian cancer. Current Opinion in Obstetrics & Gynecology. 21(1). 44–53. 15 indexed citations

19.

Collinson, Fiona, et al.. (2008). Long-term Survival and Occasional Regression of Distant Melanoma Metastases after Adrenal Metastasectomy. Annals of Surgical Oncology. 15(6). 1741–1749. 43 indexed citations

20.

Collinson, Fiona, Geoff Hall, Timothy Perren, & Gordon C. Jayson. (2007). Development of antiangiogenic agents for ovarian cancer. Expert Review of Anticancer Therapy. 8(1). 21–32. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact